Mangoceuticals, Inc.
MGRX
$4.91
-$0.37-7.01%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -45.60% | 15.58% | 112.61% | 2,646.07% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -45.60% | 15.58% | 112.61% | 2,646.07% | -- |
| Cost of Revenue | -49.60% | 72.64% | 53.33% | 2,382.93% | -- |
| Gross Profit | -42.81% | -19.86% | 157.69% | 2,810.20% | -- |
| SG&A Expenses | -6.09% | -11.33% | -13.74% | 183.11% | 75.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.54% | -2.19% | 13.63% | 163.74% | 80.39% |
| Operating Income | 2.65% | 3.32% | -8.46% | -135.84% | -55.68% |
| Income Before Tax | -11.13% | -4.70% | 7.55% | -281.18% | -80.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.13% | -4.70% | 7.55% | -281.18% | -80.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.10% | -4.68% | 7.55% | -281.18% | -80.87% |
| EBIT | 2.65% | 3.32% | -8.46% | -135.84% | -55.68% |
| EBITDA | 2.27% | 3.19% | -8.47% | -135.34% | -- |
| EPS Basic | 41.44% | 36.74% | 54.41% | -160.54% | -14.14% |
| Normalized Basic EPS | 41.44% | 36.74% | 54.42% | -160.53% | -14.13% |
| EPS Diluted | 41.44% | 36.74% | 54.41% | -160.54% | -14.14% |
| Normalized Diluted EPS | 41.44% | 36.74% | 54.42% | -160.53% | -14.13% |
| Average Basic Shares Outstanding | 89.69% | 65.48% | 102.80% | 46.31% | 58.47% |
| Average Diluted Shares Outstanding | 89.69% | 65.48% | 102.80% | 46.31% | 58.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
